← Leaderboards
Manjeet Kumar Rao
University Of Texas Hlth Science Center
$4,238,035
Attributed
$6,162,424
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $939.9K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,162,424 · 6
By mechanism
R01$5,870,910 · 4
R03$291,514 · 2
Top collaborators
- Ratna K Vadlamudi13 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Peter J Houghton$32,798,876
- Valerie Ann Cortez$55,537
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesPlayOverexpressionBiochemicalCellsProteinsChemotherapyResistanceDna RepairTriple-Negative Invasive Breast CarcinomaNovel TherapeuticsMalignant Breast NeoplasmMalignant NeoplasmsStructureTherapy ResistantPharmaceutical PreparationsRegimenLegal PatentPhase I Clinical TrialsResponseCancer CenterDna DamageDrug DevelopmentBreast Cancer Patient
Grant awards (22)
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers$484,169
R01 · FY2025 · CA · contact PI
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers$459,961
R01 · FY2024 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$377,821
R01 · FY2024 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$9,628
R01 · FY2024 · CA · contact PI
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers$484,169
R01 · FY2023 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$390,054
R01 · FY2023 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$65,662
R01 · FY2023 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$390,354
R01 · FY2022 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$41,668
R01 · FY2022 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$416,086
R01 · FY2021 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$429,261
R01 · FY2020 · CA · contact PI
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$335,582
R01 · FY2019 · CA · contact PI
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$345,962
R01 · FY2018 · CA · contact PI
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$345,853
R01 · FY2017 · CA · contact PI
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$351,000
R01 · FY2016 · CA · contact PI
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$349,847
R01 · FY2015 · CA · contact PI
Importance of Androgen regulated miRNAs in male fertility$72,881
R03 · FY2015 · HD · contact PI
Importance of Androgen regulated miRNAs in male fertility$74,750
R03 · FY2014 · HD · contact PI
Catenins: A role in spertmatogenesis and sperm maturation$297,000
R01 · FY2010 · HD · contact PI
Catenins: A role in spertmatogenesis and sperm maturation$296,833
R01 · FY2009 · HD · contact PI
Targeted Suppression of the Transcription Factor Sox9 in the Testis by Tissue-Spe$70,883
R03 · FY2007 · HD · contact PI
Targeted Suppression of the Transcription Factor Sox9$73,000
R03 · FY2006 · HD · contact PI